AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29529622 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral arthroplasty (PFA)
Number of subjects: 100
Study 29529622 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 100
Study 27279274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO, n = 63)
Number of subjects: 185
Study 27279274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO, n = 61)
Number of subjects: 185
Study 27279274 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control, n = 61)
Number of subjects: 185
Study 25157647 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 150
Study 22761293 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine for 7‐11 days
Number of subjects: 16
Study 22761293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20061261 — intervention group
Group type: EXPERIMENTAL
Intervention: In Our Own Voice (IOOV) presentation
Number of subjects: 30
Study 18076241 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion to the hip
Number of subjects: 16
Study 18076241 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion to the breast
Number of subjects: 16
Study 18076241 — intervention group
Group type: COMPARATOR
Intervention: On land
Number of subjects: 16
Study 18076241 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 16
Study 16318659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% 10 mg (Group I)
Number of subjects: 60
Study 16318659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% 17.5 mg (Group II)
Number of subjects: 60
Study 16318659 — intervention group
Group type: COMPARATOR
Intervention: Control group without spinal anaesthesia (Group III)
Number of subjects: 60
Study 12393618 — intervention group
Group type: EXPERIMENTAL
Intervention: FND (Fludarabine, mitoxantrone, dexamethasone)
Number of subjects: 142
Study 12393618 — intervention group
Group type: COMPARATOR
Intervention: ATT (alternating triple therapy)
Number of subjects: 142
Study 12393618 — intervention group
Group type: EXPERIMENTAL
Intervention: FND
Number of subjects: 142
Study 12393618 — intervention group
Group type: COMPARATOR
Intervention: ATT
Number of subjects: 142
Study 10332682 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 113
Study 10332682 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 113
Study 8565029 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg twice daily
Number of subjects: 254
Study 8565029 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 254
Study 8565029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 8565029 — intervention group
Group type: COMPARATOR
Intervention: Etodolac vs Placebo
Number of subjects: 254
Study 8565029 — intervention group
Group type: COMPARATOR
Intervention: Naproxen vs Placebo
Number of subjects: 254
Study 8565029 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac and Naproxen
Number of subjects: 254
Study 1785706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver 1V (Haemonetics)
Number of subjects: 120
Study 1785706 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltration
Number of subjects: 120
Study 7180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking and alcohol consumption
Number of subjects: 0
Study 7180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study 7180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-deprived smokers
Number of subjects: 0
Study 28786547 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 308
Study 28786547 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 308
Study 28786547 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin 100 mg
Number of subjects: 308
Study 26353789 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil (4.5 g omega-3 fatty acids) 15 mL/day
Number of subjects: 202
Study 26353789 — intervention group
Group type: COMPARATOR
Intervention: Low-dose fish oil (blend of fish oil and sunola oil; ratio of 1:9, 0.45 g omega-3 fatty acids) 15 mL/day
Number of subjects: 202
Study 24325591 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNB
Number of subjects: 28
Study 24325591 — intervention group
Group type: COMPARATOR
Intervention: EUS‐FNA
Number of subjects: 28
Study 23879825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) in addition to conventional medical treatment
Number of subjects: 0
Study 23879825 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 0
Study 23879825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 0
Study 20523087 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 on day 1 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm A)
Number of subjects: 71
Study 20523087 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 on day 8 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm B)
Number of subjects: 71
Study 18444053 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley model of family therapy for anorexia nervosa
Number of subjects: 0
Study 18444053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for bulimia nervosa
Number of subjects: 0
Study 18444053 — intervention group
Group type: COMPARATOR
Intervention: Other psychosocial interventions (family therapy, cognitive therapy, behavioral therapy)
Number of subjects: 0
Study 16620243 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nursing case management with access to a nurse case manager 24/7 and an abuse video (N = 499)
Number of subjects: 1000
Study 16620243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care management activities (support and assessing needs)
Number of subjects: 1000
Study 16620243 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1000
Study 14669180 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured speed‐dependent treadmill training (STT)
Number of subjects: 17
Study 14669180 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited progressive treadmill training (LTT)
Number of subjects: 17
Study 14669180 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (CGT)
Number of subjects: 17
Study 14669180 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 17
Study 10946099 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric trunk extension‐flexion test with different heights for the pelvic fulcrum
Number of subjects: 114
Study 10946099 — intervention group
Group type: COMPARATOR
Intervention: Isometric trunk extension‐flexion test with pelvic fulcrum at hip joint level
Number of subjects: 114
Study 8823423 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional doses of rifampicin, pyrazinamide and streptomycin every 4 weeks in the continuation phase (114 patients)
Number of subjects: 266
Study 8823423 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen without additional doses (113 patients)
Number of subjects: 266
Study 1395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid enemas (CS‐‐100 mg of hydrocortisone/60 cc P.R. q.h.s.; n = 12)
Number of subjects: 45
Study 1395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine enemas (5‐ASA‐‐4 g/60 cc P.R. q.h.s.; n = 19)
Number of subjects: 45
Study 1395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acid enemas (SCFA‐‐60 cc P.R. b.i.d.; n = 14)
Number of subjects: 45
Study 1395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment for corticosteroid enemas
Number of subjects: 45
Study 1395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment for mesalamine enemas
Number of subjects: 45
Study 1395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment for short-chain fatty acid enemas
Number of subjects: 45
Study 2857601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pinacidil, 0.2 mg/kg
Number of subjects: 6
Study 2857601 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine, 0.3 mg/kg
Number of subjects: 6
Study 31619413 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 1278
Study 31619413 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 1278
Study 28956187 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A: every-3-week ixabepilone (32 mg/m2 on day 2) + vorinostat (300 mg daily, days 1-14)
Number of subjects: 37
Study 28956187 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B: weekly ixabepilone (16 mg/m2 on days 2, 9, 16) + vorinostat (300 mg daily, days 1-7; 15-21)
Number of subjects: 37
Study 26745614 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CM)
Number of subjects: 23
Study 26745614 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular Matrix (ECM)
Number of subjects: 23
Study 25358221 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily before meal for 4 consecutive days monthly for 3 months
Number of subjects: 386
Study 25358221 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg daily after meals for 3 months
Number of subjects: 386
Study 22680315 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened volunteers
Number of subjects: 156
Study 22680315 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized volunteers
Number of subjects: 156
Study 20182883 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.5 ml dexamethasone diphosphate (10 mg)
Number of subjects: 34
Study 20182883 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml placebo
Number of subjects: 34
Study 19087677 — intervention group
Group type: EXPERIMENTAL
Intervention: TXL capsule
Number of subjects: 70
Study 19087677 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 70
Study 17469415 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) for therapeutic indications
Number of subjects: 0
Study 17469415 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive methods for post-ERCP pancreatitis
Number of subjects: 0
Study 17469415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic endotherapy
Number of subjects: 0
Study 17469415 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary team approach
Number of subjects: 0
Study 17469415 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of unestablished methods
Number of subjects: 0
Study 12032630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction (50 mmol)
Number of subjects: 24
Study 12032630 — intervention group
Group type: COMPARATOR
Intervention: Liberal sodium intake (200 mmol)
Number of subjects: 24
Study 10191222 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 0
Study 10191222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7473519 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for hypertension
Number of subjects: 850
Study 1915197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 8
Study 1915197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1915197 — intervention group
Group type: EXPERIMENTAL
Intervention: Large neutral amino acids (LNAA)
Number of subjects: 8
Study 342623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent A/Victoria/75-A/New Jersey/76 influenza vaccine
Number of subjects: 0
Study 342623 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent B/Hong Kong/72 influenza vaccine
Number of subjects: 0
Study 342623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent A/Victoria/75-A/New Jersey/76 and Monovalent B/Hong Kong/72 influenza vaccines (given together)
Number of subjects: 0
Study 342623 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 0
Study 30784893 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI group
Number of subjects: 0
Study 30784893 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27589995 — intervention group
Group type: EXPERIMENTAL
Intervention: L-serine (0.5, 2.5, 7.5, or 15 g/dose, twice daily)
Number of subjects: 20
Study 27589995 — intervention group
Group type: COMPARATOR
Intervention: Matched historical placebo controls from five previous ALS therapeutic trials
Number of subjects: 20
Study 26135703 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397
Study 26135703 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397
Study 26135703 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 397
Study 26135703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 22345689 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational program (EP) in cardiovascular prevention (CVP) for children
Number of subjects: 197
Study 22345689 — intervention group
Group type: COMPARATOR
Intervention: Written educational material (EM) for parents about healthy lifestyle (Control)
Number of subjects: 197
Study 16778262 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 4 weeks
Number of subjects: 68
Study 16778262 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP for 4 weeks
Number of subjects: 68
Study 16778262 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 68
Study 16778262 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 68
Study 15290417 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg oral premedication 1 hour before induction
Number of subjects: 24
Study 15290417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atenolol)
Number of subjects: 24
Study 11008910 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple outcall intervention
Number of subjects: 983
Study 11008910 — intervention group
Group type: COMPARATOR
Intervention: Single outcall intervention
Number of subjects: 983
Study 11008910 — intervention group
Group type: COMPARATOR
Intervention: Health survey only (control)
Number of subjects: 983
Study 11008910 — intervention group
Group type: COMPARATOR
Intervention: Advance card + single outcall
Number of subjects: 983
Study 9360203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg q6h)
Number of subjects: 45
Study 9360203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1490692 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 1490692 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study 2986300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 19
Study 2986300 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study 2986300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide
Number of subjects: 19
Study 2986300 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with hydrochlorothiazide
Number of subjects: 19
Study 30892844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance therapy
Number of subjects: 0
Study 30892844 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 28012564 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate at a starting dose of 17.5 mg/week for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Number of subjects: 120
Study 28012564 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Number of subjects: 120
Study 27481744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric enteral nutrition (15 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Number of subjects: 120
Study 27481744 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric enteral nutrition (25 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Number of subjects: 120
Study 24816958 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) injection (20 U into internal anal sphincter)
Number of subjects: 41
Study 24816958 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream (thrice daily for 6 weeks)
Number of subjects: 41
Study 24816958 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) injection (20 U)
Number of subjects: 41
Study 24816958 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream
Number of subjects: 41
Study 22879656 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.15 mg kg(‐1)
Number of subjects: 147
Study 22879656 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.5 mg kg(‐1)
Number of subjects: 147
Study 22879656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 147
Study 19662630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-20 mg/day)
Number of subjects: 722
Study 19662630 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant (ADT) monotherapy
Number of subjects: 722
Study 17565929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination latanoprost/timolol
Number of subjects: 1052
Study 15155718 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 42
Study 11593092 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (40-55% HRres)
Number of subjects: 126
Study 11593092 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise (65-80% HRres)
Number of subjects: 126
Study 11593092 — intervention group
Group type: COMPARATOR
Intervention: Control group (minimally supervised home-based exercise)
Number of subjects: 126
Study 9638417 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study 9638417 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg peroral
Number of subjects: 40
Study 9638417 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 100 microgram subcutaneously
Number of subjects: 40
Study 9638417 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil plus SMS 201-995
Number of subjects: 40
Study 8135390 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 20
Study 8135390 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 20
Study 2554500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin fraction CY 216
Number of subjects: 0
Study 2554500 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 30907678 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART intervention (delivered online or in-person)
Number of subjects: 50
Study 28590828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg qd
Number of subjects: 162
Study 28590828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg bid
Number of subjects: 162
Study 28590828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg qd
Number of subjects: 162
Study 28590828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 25425015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine hydrochloride
Number of subjects: 281
Study 25425015 — intervention group
Group type: COMPARATOR
Intervention: Felodipine sustained-release tablets
Number of subjects: 281
Study 24133618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 50
Study 24133618 — intervention group
Group type: COMPARATOR
Intervention: Healthy nutritional recommendation (HNR) diet
Number of subjects: 50
Study 21681154 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Rope Training
Number of subjects: 25
Study 21681154 — intervention group
Group type: EXPERIMENTAL
Intervention: Rope Training
Number of subjects: 25
Study 21681154 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 20031845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel, multicomponent intervention (interactive computerized hypertension education, home BP monitoring, monthly behavioral counseling)
Number of subjects: 30
Study 20031845 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 20031845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel, multicomponent intervention
Number of subjects: 30
Study 16678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d for up to 12 months
Number of subjects: 581
Study 16678643 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg/d for up to 12 months
Number of subjects: 581
Study 16678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d
Number of subjects: 581
Study 16678643 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg/d
Number of subjects: 581
Study 16678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 581
Study 15379423 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST1-MRI
Number of subjects: 48
Study 15379423 — intervention group
Group type: COMPARATOR
Intervention: Routine MRI
Number of subjects: 48
Study 15379423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic hyperintense signal
Number of subjects: 48
Study 11179329 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0
Study 11179329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11179329 — intervention group
Group type: COMPARATOR
Intervention: Healthy U.S. controls
Number of subjects: 0
Study 9412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole (7.5 mg over 1 hour, followed by a continuous daily infusion of 10 mg for up to 5 days)
Number of subjects: 721